This study demonstrates superior antibacterial and anticancer properties in zinc oxide-copper oxide nanoparticles, implying potential in biomedical applications.
This study pioneers the biogenic synthesis of zinc oxide-copper oxide (ZnO-CuO) bimetallic nanoparticles (BNPs) using Theobroma cacao L. leaf extract, offering a novel and eco-friendly approach to nanoparticle development. Characterization techniques, including UV-visible spectroscopy and FTIR analysis, confirmed successful synthesis, while XRD revealed the crystalline nature of ZnO and CuO NPs, with ZnO-CuO BNPs exhibiting face-centered cubic (FCC) and hexagonal Wurtzite structures. FESEM and HRTEM analyses provided insights into morphology, and zeta potential measurements (−35.4, −36.1, and −46.9 mV) demonstrated nanoparticle stability. Thermal properties were assessed using TGA and DSC. ZnO-CuO BNPs exhibited superior biological activity compared to their monometallic counterparts. They demonstrated significant antibacterial, antioxidant, and angiogenic properties in a dose-dependent manner. In in vitro cytotoxicity assays, ZnO-CuO BNPs showed enhanced anticancer efficacy, with IC50 values against HCT-15 cells at 8.27 ± 0.47 µg/mL and against A549 cells at 7.28 ± 0.09 µg/mL, outperforming ZnO and CuO nanoparticles. Additionally, ZnO-CuO BNPs displayed a remarkable anti-ROS effect, highlighting their therapeutic potential. These findings underscore the superiority of ZnO-CuO BNPs over monometallic nanoparticles, positioning them as promising candidates for biomedical applications, particularly in antibacterial and anticancer therapies.
No takes yet. Share an insight, caveat, or question.
Poojari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: